VALACYCLOVIR HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Valacyclovir Hydrochloride patents expire, and when can generic versions of Valacyclovir Hydrochloride launch?
Valacyclovir Hydrochloride is a drug marketed by Apotex, Aurobindo Pharma, Chartwell Rx, Cipla, Graviti Pharms, Hetero Labs Ltd V, Hikma, Jubilant Generics, Mylan Pharms Inc, Norvium Bioscience, Sandoz, Sun Pharm Inds Ltd, Teva Pharms, Watson Labs Inc, Yiling, and Zydus Lifesciences. and is included in sixteen NDAs.
The generic ingredient in VALACYCLOVIR HYDROCHLORIDE is valacyclovir hydrochloride. There are twenty-three drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the valacyclovir hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valacyclovir Hydrochloride
A generic version of VALACYCLOVIR HYDROCHLORIDE was approved as valacyclovir hydrochloride by SUN PHARM INDS LTD on January 31st, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VALACYCLOVIR HYDROCHLORIDE?
- What are the global sales for VALACYCLOVIR HYDROCHLORIDE?
- What is Average Wholesale Price for VALACYCLOVIR HYDROCHLORIDE?
Summary for VALACYCLOVIR HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 16 |
Finished Product Suppliers / Packagers: | 39 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 120 |
Patent Applications: | 1,375 |
DailyMed Link: | VALACYCLOVIR HYDROCHLORIDE at DailyMed |